Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034759 | 0.87 | NPC1 (0.51) | RAB9ANPC1MAPTALDH1A1CHRNB2 | |
| SCHEMBL2037569 | 0.87 | RAB9A (0.55) | RAB9ANPC1MAPTALDH1A1KDM4E | |
| SCHEMBL2039501 | 0.85 | NPC1 (0.46) | RAB9ANPC1MAPTALDH1A1KDM4E | |
| SCHEMBL2040629 | 0.81 | NPC1 (0.51) | RAB9ANPC1MAPTCHRNB2CHRNA5 | |
| SCHEMBL2039666 | 0.80 | NPC1 (0.46) | RAB9ANPC1MAPTALDH1A1KDM4E | |
| SCHEMBL2035283 | 0.79 | CHRNB2 (0.72) | RAB9ANPC1MAPTCHRNB2CHRNA5 | |
| SCHEMBL2037946 | 0.79 | CHRNB2 (0.72) | RAB9ANPC1MAPTALDH1A1KDM4E | |
| SCHEMBL2037580 | 0.77 | NPC1 (0.46) | RAB9ANPC1MAPTALDH1A1KDM4E | |
| SCHEMBL2036752 | 0.74 | NPC1 (0.46) | RAB9ANPC1MAPTALDH1A1CHRNB2 | |
| SCHEMBL2118901 | 0.72 | GRM5 (0.59) | RAB9ANPC1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-12-06 | — | — | US | claimed |
| EP-2513087-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NeuroSearch A/S (DK) | 2012-10-24 | — | — | EP | claimed |
| WO-2011073297-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NEUROSEARCH A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-12-06 | — | — | US | disclosed |
| EP-2513087-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NeuroSearch A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073297-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NEUROSEARCH A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA5, CHRNA7, CHRNA3 | RAB9A 2992/4885NPC1 3279/4885MAPT 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.